Recent Updates
Recently added Catalysts

Allogeneic DCs and Autologous RCC Tumor Derived Cells

Phase 1

Carcinoma, Renal Cell | Small molecule | Oncology |Sanofi|Last Updated: Mar 5, 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment30

FDA Designations

No designations recorded

Clinical trial landscape

Allogeneic DCs and Autologous RCC Tumor Derived Cells · 1 trial · 1 indication

Phase 1 1
NCT00050323Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney CancerCarcinoma, Renal Cell
COMPLETED30 Analytics
PHASE1COMPLETED
Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer
Carcinoma, Renal Cell
NCT0005032330
Unlock trial analytics

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
Allogeneic DCs and Autologous RCC Tumor Derived CellsDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: * The patient must be greater than or equal to 18 years of age. * The patient must be diagnosed with AJCC Stage IV (primary or relapsed) Renal Cell Carcinoma. * The patient must have a Screening Eastern Cooperative Oncology Group (ECOG) Clinical Performance Status of 0-1. * The ...

Countries:United States
Unlock Eligibility Criteria